FOR IMMEDIATE RELEASE

MULTICASE Inc. Announces a renewal of Cooperative Research And Development Agreement with the Food and Drug Administration.

CLEVELAND, Ohio · Octover 1, 2004 · MULTICASE Inc., a leading supplier of Artificial Intelligence Software for the development of new drugs and the assessment of their biological activities, today announced that it had renewed the Cooperative Research and Development Agreement (CRADA) with the U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) for another five years. Under this CRADA, the FDA will use the Company’s M-CASE Software to develop a panel of toxicity database modules to provide toxicology decision support information for regulatory, research and development applications. The principal investigators for the FDA are Dr. Joseph F. Contrera and Dr. Edwin J. Matthews in the Office of Research and Testing.

MULTICASE will market and distribute the resulting software to industry, academia, regulatory agencies and other interested clients.

[ Home ] [ Up ] [ Feedback ] [ Contents ] [ Search ] [ Contacts ] [ Publications ] [ FAQ ] [ Support ] [ About Us ]

Send mail to saiakhov@multicase.com with questions or comments about this web site.
Copyright © 2011 Multicase Inc
Last modified: 08/01/11

MultiCASE MC4PC-based computational toxicology estimations are intended to be used as part of a weight of evidence approach for hazard and risk assessment that includes laboratory experimental data. Computational toxicology predictions are not intended as a substitute for appropriate animal or clinical studies. Results obtained with certain MC4PC software modules should be regarded as preliminary and subject to change.